The revolving door turns again.
Scott Gottlieb walks through the revolving door to the Pfizer board
By ED SILVERMAN @Pharmalot JUNE 27, 2019
After a two-year stint running the Food and Drug Administration, Scott Gottlieb has joined the board of directors at Pfizer, giving the world’s largest drug maker crucial insights into the inner workings of the Trump administration as it attempts to contain national angst over the rising cost of medicines.
And in doing so, Gottlieb is also picking up where he left before joining the agency, since he had been on the board of several smaller pharmaceutical companies and was also a partner at a venture capital firm that invests in life sciences companies.
“This is classic and it’s not surprising,” said Sidney Wolfe, a founder of Public Citizen Health Research Group and a long-time FDA watchdog, who had expressed concern about Gottlieb’s ties to industry before joining the agency. “Philosophically, he’s returning to the ecosystem where he’s most comfortable. And he’ll get paid very well for it, too.”
Last year, Pfizer board members — who are not employees — were given cash retainers of $142,500, plus Pfizer stock units that in 2019 are expected to be worth roughly $159,000. The board met seven times in 2018, although board members also sit on specific committees that also hold meetings.
more:
http://www.statnews.com/pharmalot/2019/06/27/scott-gottlieb-pfizer-board-fda/?fbclid=IwAR1aKJz6REPH6WU7a90VwljArRa00ti0fm8Jytr2tHnPywAi9ehImW8_GIg
DO SOMETHING!
| 